This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Oct;19(10):1367-1369.

doi: 10.1080/14740338.2020.1812191. Epub 2020 Aug 25.

Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?

Emanuel Raschi¹, Paolo Caraceni¹, Elisabetta Poluzzi¹, Fabrizio De Ponti¹

Affiliations

PMID: 32840116
DOI: 10.1080/14740338.2020.1812191

Comment

Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?

Emanuel Raschi et al. Expert Opin Drug Saf. 2020 Oct.

. 2020 Oct;19(10):1367-1369.

doi: 10.1080/14740338.2020.1812191. Epub 2020 Aug 25.

Authors

Emanuel Raschi¹, Paolo Caraceni¹, Elisabetta Poluzzi¹, Fabrizio De Ponti¹

Affiliation

¹ Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna , Bologna, Italy.

PMID: 32840116
DOI: 10.1080/14740338.2020.1812191

No abstract available

PubMed Disclaimer

Comment in

Reply to letter to the editor: baricitinib and toxicity is a rare occurrence.
Peng L, Stebbing J, Wang YJ. Peng L, et al. Expert Opin Drug Saf. 2020 Oct;19(10):1371-1372. doi: 10.1080/14740338.2020.1812192. Epub 2020 Aug 24. Expert Opin Drug Saf. 2020. PMID: 32804556 No abstract available.

Comment on

A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. Peng L, et al. Expert Opin Drug Saf. 2020 Nov;19(11):1505-1511. doi: 10.1080/14740338.2020.1799975. Epub 2020 Jul 31. Expert Opin Drug Saf. 2020. PMID: 32693646

Similar articles

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, Aquilini D, Landini G, Cimolato B, Pietro MAD, Trezzi M, Stobbione P, Frausini G, Navarra A, Nicastri E, Sotgiu G, Goletti D. Cantini F, et al. J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24. J Infect. 2020. PMID: 32592703 Free PMC article.
Baricitinib for COVID-19: a suitable treatment?
Favalli EG, Biggioggero M, Maioli G, Caporali R. Favalli EG, et al. Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3. Lancet Infect Dis. 2020. PMID: 32251638 Free PMC article. No abstract available.
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
Richardson PJ, Corbellino M, Stebbing J. Richardson PJ, et al. Lancet Infect Dis. 2020 Sep;20(9):1013-1014. doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3. Lancet Infect Dis. 2020. PMID: 32251639 Free PMC article. No abstract available.
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M, Pornour M, Mansouri D. Seif F, et al. Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11. Int Arch Allergy Immunol. 2020. PMID: 32392562 Free PMC article. Review.
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Jorgensen SCJ, et al. Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27. Pharmacotherapy. 2020. PMID: 32542785 Free PMC article. Review.

See all similar articles

Cited by

Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the "ACO-VID" Registry.
Cerezo Manchado JJ, Iturbe Hernández T, Martínez Pacheco MDC, Gil Ortega I, Campoy D, Canals Pernas T, Martinez Serra L, Flores Aparco KJ, Velasquez Escandon CA, García de Guadiana-Romualdo L, Martinez Frances A, Olivera P. Cerezo Manchado JJ, et al. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231208440. doi: 10.1177/10760296231208440. Clin Appl Thromb Hemost. 2023. PMID: 37899606 Free PMC article.
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).
Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. Elahi R, et al. Int Immunopharmacol. 2022 Apr;105:108536. doi: 10.1016/j.intimp.2022.108536. Epub 2022 Jan 11. Int Immunopharmacol. 2022. PMID: 35074571 Free PMC article. Review.
Effect of SARS-CoV-2 infection on the liver.
Sanyaolu A, Marinkovic A, Abbasi AF, Prakash S, Patidar R, Desai P, Williams M, Jan A, Hamdy K, Solomon R, Balendra V, Ansari M, Shazley O, Khan N, Annan R, Dixon Y, Okorie C, Antonio A. Sanyaolu A, et al. World J Virol. 2023 Mar 25;12(2):109-121. doi: 10.5501/wjv.v12.i2.109. World J Virol. 2023. PMID: 37033147 Free PMC article. Review.
COVID-19-related liver injury: Focus on genetic and drug-induced perspectives.
Parchwani D, Sonagra AD, Dholariya S, Motiani A, Singh R. Parchwani D, et al. World J Virol. 2023 Jan 25;12(1):53-67. doi: 10.5501/wjv.v12.i1.53. World J Virol. 2023. PMID: 36743658 Free PMC article.
Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol.
Cerezo-Manchado JJ, Meca Birlanga O, García de Guadiana Romualdo L, Gil-Ortega I, Martínez Francés A, Iturbe-Hernandez T. Cerezo-Manchado JJ, et al. Drugs Context. 2022 Jan 24;11:2021-9-4. doi: 10.7573/dic.2021-9-4. eCollection 2022. Drugs Context. 2022. PMID: 35145555 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon